pipobroman has been researched along with busulfan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Hino, K; Koike, T; Sakashita, A; Sato, S; Tomoyasu, S; Tsuruoka, N | 1 |
| Ansari, A; Jamshidi, K; Swaim, WR; Windschitl, HE | 1 |
| Hoshi, A; Kanzawa, F; Kuretani, K | 1 |
| Brichta, G; Reimer, EE; Stoiber, T | 1 |
| Boivin, P; Dormont, J; Soulier, JP; Vallée, G | 1 |
| Durán Suárez, JR; Juncá Piera, J; Triginer Boixeda, J | 1 |
| Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ | 1 |
| Nevado Reviriego, I; Román Barbero, A; Sánchez Fayos, J | 1 |
| Tefferi, A | 1 |
| Gisslinger, B; Gisslinger, H; Heis, N; Knöbl, P; Lechner, K; Rintelen, C | 1 |
| Fabris, F; Girolami, A; Randi, ML | 2 |
| Bertola, G; Lodato, A; Sciariada, L; Sironi, M; Spinelli, M | 1 |
| Newberry, KJ; Sever, M; Verstovsek, S | 1 |
| Barbui, T; Tefferi, A | 1 |
| Broome, AM; Jiang, YL | 1 |
4 review(s) available for pipobroman and busulfan
| Article | Year |
|---|---|
[Megakaryoblastic transformation associated with disseminated intravascular coagulation in the course of polycythemia vera: a case report].
Topics: Blast Crisis; Busulfan; Carbazilquinone; Disseminated Intravascular Coagulation; Humans; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Pipobroman; Polycythemia Vera | 1992 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; Busulfan; Female; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Incidence; Interferon-alpha; Ischemic Attack, Transient; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Leukemia, Radiation-Induced; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Controlled Trials as Topic; Survival Rate | 1997 |
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2014 |
15 other study(ies) available for pipobroman and busulfan
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Hepatomegaly; Humans; Male; Melphalan; Middle Aged; Oral Hemorrhage; Phosphorus Isotopes; Pipobroman; Polycythemia Vera; Splenomegaly; Thrombocythemia, Essential; Thrombosis; Tooth Extraction | 1973 |
Antitumor activity of haloacetylphenothiazines against ascites sarcoma-180.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Iodoacetates; Mice; Neoplasm Transplantation; Phenothiazines; Pipobroman; Sarcoma 180; Thiotepa | 1972 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Pipobroman; Prednisolone; Vincristine | 1968 |
[Chronic myelosis. Clinical picture and therapy].
Topics: Antineoplastic Agents; Busulfan; Chronic Disease; Gold Isotopes; Leukemia, Myeloid; Pipobroman; Spleen | 1969 |
[Present treatment of the Vaquez's disease].
Topics: Aged; Anemia; Anticoagulants; Antineoplastic Agents; Blood Donors; Blood Volume; Bloodletting; Busulfan; Cerebral Hemorrhage; Hematuria; Humans; Leukemia, Radiation-Induced; Leukocytosis; Peptic Ulcer; Phosphorus Isotopes; Pipobroman; Polycythemia Vera; Postoperative Complications; Splenomegaly; Thrombocytopenia; Thrombosis; Vascular Diseases | 1969 |
[Osteolytic lesions in chronic myeloid leukemia. Report of three cases (author's transl)].
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Busulfan; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Osteolysis; Pipobroman; Prednisone; Prognosis; Radiography; Vincristine | 1981 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chromosomes, Human, Pair 17; Diagnosis, Differential; Disease Progression; Humans; Hydroxyurea; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Pipobroman; Polycythemia Vera; Research Design; Retrospective Studies; Risk; Thrombocythemia, Essential | 1998 |
The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Drug Tolerance; Erysipelas; Erythropoiesis; Female; Hematocrit; Humans; Hydroxyurea; Interferon-alpha; Leukopoiesis; Male; Middle Aged; Phlebotomy; Pipobroman; Polycythemia Vera; Syncope; Thrombosis; Time Factors; Treatment Outcome | 1999 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Phosphorus Radioisotopes; Pipobroman; Retrospective Studies; Thrombocythemia, Essential | 1999 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Phosphorus Radioisotopes; Pipobroman; Thrombocythemia, Essential | 2000 |
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Humans; Hydroxyurea; Leukemia, Megakaryoblastic, Acute; Male; Megakaryocytes; Middle Aged; Pipobroman; Thrombocythemia, Essential; Time Factors | 2003 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thrombocythemia, Essential; Thrombosis; Young Adult | 2019 |
Novel Pyrene Excimer and Fluorogenic Probe for the Detection of Alkylating Agents.
Topics: Alkylating Agents; Antineoplastic Agents; Busulfan; Chemical Warfare Agents; Fluorescent Dyes; Mustard Gas; Pipobroman; Pyrenes; Salicylates; Spectrometry, Fluorescence; Temozolomide | 2019 |